RxDoctor Payments Data

Kevin Williams, APRN

Nurse Practitioner · Tampa, FLNPI 1083754048

Payments from drug & device makers

$18,822in general payments, 2019–2025

Across 279 payments — averaging $67.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$4K
  • Axsome Therapeutics, Inc.$3K
  • Otsuka America Pharmaceutical, Inc.$3K
  • Gilead$2K
  • Viiv Healthcare Company$2K
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$2K
  • plus $2K from 11 others

What the payments were for

  • Consulting fees$7,40839%
  • Speaking & faculty fees$1,5758%
  • Travel & lodging$3,25817%
  • Food & beverage$6,39734%
  • Education$1841%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,822 in reported general payments places this provider in the 95th percentile of 8,290 nurse practitioner providers in Florida.

See all nurse practitioner providers in Florida

Medicare billing

Part B allowed, 2024
$2,669
Medicare patients
15
Services billed
37

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TivicayDolutegravir Sodium100$244,998
OdefseyEmtricitab/Rilpiviri/Tenof Ala70$244,101
GenvoyaElviteg/Cob/Emtri/Tenof Alafen59$240,176
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf50$230,016
JulucaDolutegravir/Rilpivirine40$146,608
BiktarvyBictegrav/Emtricit/Tenofov Ala30$123,939
TriumeqAbacavir/Dolutegravir/Lamivudi28$110,985
DescovyEmtricitabine/Tenofov Alafenam52$110,174
Darunavir25$33,532
PrezistaDarunavir16$31,472
SelzentryMaraviroc13$22,613
JardianceEmpagliflozin21$12,572
Etravirine11$11,609
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr16$9,205
JanumetSitagliptin Phos/Metformin Hcl16$9,045

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Viiv Healthcare CompanyTivicay, Juluca, Triumeq$1,968$502,591168 claims
GileadGenvoya, Biktarvy, Descovy$1,995$474,290141 claims
Janssen Products, LPSymtuza$99$230,01650 claims
Janssen Scientific Affairs, LLCPrezista$102$31,47216 claims
MerckJanumet$666$9,04516 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,290 nurse practitioner providers in Florida.

Other nurse practitioner in Tampa

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →